AR086896A1 - COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO - Google Patents
COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICOInfo
- Publication number
- AR086896A1 AR086896A1 ARP120102063A ARP120102063A AR086896A1 AR 086896 A1 AR086896 A1 AR 086896A1 AR P120102063 A ARP120102063 A AR P120102063A AR P120102063 A ARP120102063 A AR P120102063A AR 086896 A1 AR086896 A1 AR 086896A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- cycloalkyl
- formula
- activity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 title 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 title 1
- 230000001800 adrenalinergic effect Effects 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000006588 heterocycloalkylene group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 abstract 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000732 arylene group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Procesos para su preparación, composiciones que los comprenden, usos terapéuticos y combinaciones con otros ingredientes farmacéuticamente activos.Reivindicación 1: Un compuesto caracterizado porque es de fórmula general (1), donde Q es un grupo de fórmula (Q1) a (Q6); Z es H o OH; Y es -(CH2)n- donde n es un entero entre 1 y 12 o es un grupo divalente de fórmula (2) donde A1 y A2 en forma independiente entre sí están ausentes o se seleccionan entre el grupo que consiste en alquileno C1-6, cicloalquileno C3-8 y heterocicloalquileno C3-8; B se encuentra ausente o se selecciona entre el grupo que consiste en cicloalquileno C3-8, heterocicloalquileno C3-8, arileno y heteroarileno o es un grupo de fórmula (3); C se encuentra ausente o se selecciona entre el grupo que consiste en -O-, -OCO-, -C(O)O-, -S-, -S(O)-, -S(O)2- y -N(R4)- o es uno de los restos del grupo de fórmulas (4) donde R4 es H o se selecciona entre el grupo que consiste en alquilo C1-8, cicloalquilo C3-8, heterocicloalquilo C3-8, arilo y heteroarilo; D se selecciona entre el grupo que consiste en alquileno C1-12, alquenileno C2-12 y alquinileno C2-6, opcionalmente sustituido con uno o más alquilo C1-6; R es -H o alquilo C1-4; X es -O- ó -S-; R1 es H o se selecciona entre el grupo que consiste en cicloalquilo C3-8, arilo, heteroarilo, arilalquilo C1-6, heteroarilalquilo C1-6 y cicloalquil C3-8alquilo C1-6, opcionalmente sustituido con uno o más alcoxi C1-4; R2 se selecciona entre el grupo que consiste en cicloalquilo C3-8, arilo, heteroarilo, arilalquilo C1-6, heteroarilalquilo C1-6 y cicloalquil C3-8alquilo C1-6, opcionalmente sustituido con uno o más átomos de halógeno o alcoxi C1-4; R3 es H o se selecciona entre el grupo que consiste en -OH, hidroxialquilo C1-6, -N(R5R6) y -N(R5)CO(R6); R5 y R6 son en forma independiente H o alquilo C1-6; y sales aceptables farmacéuticamente o solvatos del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169535 | 2011-06-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086896A1 true AR086896A1 (es) | 2014-01-29 |
Family
ID=46458445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120102063A AR086896A1 (es) | 2011-06-10 | 2012-06-08 | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9012644B2 (es) |
| EP (1) | EP2718281B1 (es) |
| KR (2) | KR20180085068A (es) |
| CN (1) | CN103547575B (es) |
| AR (1) | AR086896A1 (es) |
| BR (1) | BR112013030302B1 (es) |
| CA (1) | CA2838777C (es) |
| RU (1) | RU2606121C2 (es) |
| TW (1) | TWI545121B (es) |
| WO (1) | WO2012168349A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| JP6421989B2 (ja) | 2012-12-06 | 2018-11-14 | チエシ ファルマスティスィ エス．ピー．エー． | ムスカリン受容体アンタゴニストおよびβ２アドレナリン受容体アゴニスト活性を有する化合物 |
| AR093832A1 (es) | 2012-12-06 | 2015-06-24 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO |
| MA38260B1 (fr) | 2012-12-18 | 2018-04-30 | Almirall Sa | Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TWI703138B (zh) * | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| AR104828A1 (es) | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO |
| EP3375781A4 (en) * | 2015-07-21 | 2019-01-09 | Sichuan Haisco Pharmaceutical Co., Ltd. | BENZORING DERIVATIVE WITH B2 RECEPTOR AGONIST AND M3 RECEPTOR ANTAGONIST ACTIVITIES AND USE THEREOF IN MEDICINE |
| WO2017093208A1 (en) | 2015-12-03 | 2017-06-08 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| WO2018011090A1 (en) | 2016-07-13 | 2018-01-18 | Chiesi Farmaceutici S.P.A. | Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| JP7208142B2 (ja) * | 2017-01-30 | 2023-01-18 | シエッシ ファーマスーティシ エス．ピー．エー． | Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体 |
| TW201835041A (zh) * | 2017-02-17 | 2018-10-01 | 印度商托仁特生技有限公司 | 具β-腎上腺素促效劑及抗蕈毒活性化合物 |
| TW202019923A (zh) * | 2018-07-16 | 2020-06-01 | 義大利商吉斯藥品公司 | 作為Ｒｈｏ－激酶抑制劑之酪胺酸醯胺衍生物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| US6417367B1 (en) | 2000-08-11 | 2002-07-09 | Pfizer Inc. | Methods of making quinoline amides |
| TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| WO2004101525A1 (en) | 2003-05-08 | 2004-11-25 | Theravance, Inc. | Crystalline form of aryl aniline beta-2 adrenergic receptor agonist |
| ES2329133T3 (es) * | 2003-05-28 | 2009-11-23 | Theravance, Inc. | Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos. |
| CA2543858C (en) | 2003-11-21 | 2014-04-15 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| WO2006023457A1 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| WO2006023460A2 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| NZ579244A (en) | 2007-02-28 | 2012-04-27 | Cipla Ltd | Process for preparing isomers of carmoterol |
| EP2080523A1 (en) | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| CN103936716B (zh) | 2009-04-23 | 2016-09-07 | 施万呼吸有限责任公司 | 具蕈毒碱受体拮抗剂和β2肾上腺素受体激动剂活性的二酰胺化合物 |
| WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| EP2718280B1 (en) | 2011-06-10 | 2015-09-16 | Chiesi Farmaceutici S.p.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
-
2012
- 2012-06-07 WO PCT/EP2012/060782 patent/WO2012168349A1/en not_active Ceased
- 2012-06-07 CA CA2838777A patent/CA2838777C/en not_active Expired - Fee Related
- 2012-06-07 CN CN201280024634.XA patent/CN103547575B/zh not_active Expired - Fee Related
- 2012-06-07 KR KR1020187020728A patent/KR20180085068A/ko not_active Ceased
- 2012-06-07 KR KR1020137032137A patent/KR101906630B1/ko not_active Expired - Fee Related
- 2012-06-07 RU RU2013154590A patent/RU2606121C2/ru active
- 2012-06-07 BR BR112013030302-6A patent/BR112013030302B1/pt not_active IP Right Cessation
- 2012-06-07 EP EP12732561.1A patent/EP2718281B1/en active Active
- 2012-06-08 AR ARP120102063A patent/AR086896A1/es not_active Application Discontinuation
- 2012-06-08 US US13/492,188 patent/US9012644B2/en not_active Expired - Fee Related
- 2012-06-08 TW TW101120663A patent/TWI545121B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN103547575A (zh) | 2014-01-29 |
| BR112013030302A2 (pt) | 2017-06-27 |
| CA2838777A1 (en) | 2012-12-13 |
| BR112013030302B1 (pt) | 2021-08-24 |
| TWI545121B (zh) | 2016-08-11 |
| KR101906630B1 (ko) | 2018-10-10 |
| US9012644B2 (en) | 2015-04-21 |
| CN103547575B (zh) | 2016-08-17 |
| RU2013154590A (ru) | 2015-06-20 |
| KR20180085068A (ko) | 2018-07-25 |
| WO2012168349A1 (en) | 2012-12-13 |
| EP2718281B1 (en) | 2015-09-09 |
| TW201302728A (zh) | 2013-01-16 |
| EP2718281A1 (en) | 2014-04-16 |
| KR20140028055A (ko) | 2014-03-07 |
| RU2606121C2 (ru) | 2017-01-10 |
| US20130034504A1 (en) | 2013-02-07 |
| CA2838777C (en) | 2019-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086896A1 (es) | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO | |
| AR093832A1 (es) | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARINICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENERGICO | |
| PE20141614A1 (es) | Compuestos con actividad antagonista de los receptores muscarinicos y actividad agonista del receptor beta2 adrenergico | |
| AR101106A1 (es) | Inhibidores de tirosina quinasa de bruton | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR080057A1 (es) | Piridinas disustituidas como anticancerigenos | |
| AR060994A1 (es) | Derivados de triazolopirazina | |
| AR082889A1 (es) | Compuestos y composiciones para la inhibicion de nampt | |
| AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
| AR086828A1 (es) | Compuestos heterociclicos fusionados como moduladores del canal ionico | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| AR087311A1 (es) | Quinolinas sustituidas y su uso como medicamentos | |
| AR085549A1 (es) | DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA | |
| AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
| MY170822A (en) | Ethynyl derivatives as mglur5 allosteric modulators | |
| CY1122231T1 (el) | Υποκατεστημενες 2-θειοξο-ιμιδαζολιδιν-4-ονες και σπειρο αναλογα αυτων, δραστικο αντικαρκινικο συστατικο, φαρμακευτικη συνθεση, φαρμακευτικο σκευασμα, μεθοδος για θεραπεια του καρκινου του προστατη | |
| AR077819A1 (es) | Compuestos heterociclicos antagonistas de esfingosina -1-fosfato (sip) | |
| AR085236A1 (es) | Compuestos de benzodioxol-piperazina como moduladores de los receptores 5-hty d | |
| ECSP13012980A (es) | Derivados de fenil- o piridinil-etinilo | |
| BR112013008675A2 (pt) | métodos e composições para o tratamento de diabetes e dislipidemia | |
| AR085817A1 (es) | Derivados de isoxazolidina | |
| PE20130179A1 (es) | Nuevos derivados terciarios de 8-hidroxiquinolina-7-carboxamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |